Cryosite Limited (AU:CTE)
ASX:CTE
Want to see AU:CTE full AI Analyst Report?
CTE Stock Chart & Stats
AU$1.00
-AU$0.05(-6.02%)
At close: 4:00 PM EST
AU$1.00
-AU$0.05(-6.02%)
Day’s Range― - ―
52-Week RangeAU$0.60 - AU$1.30
Previous CloseN/A
Volume1.46K
Average Volume (3M)1.97K
Market Cap
AU$56.13M
Enterprise ValueAU$60.95M
Total Cash (Recent Filing)AU$2.54M
Total Debt (Recent Filing)AU$8.82M
Price to Earnings (P/E)10.7
Beta-0.30
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.04
Shares Outstanding48,809,563
10 Day Avg. Volume3,337
30 Day Avg. Volume1,969
Financial Highlights & Ratios
PEG Ratio8.08
Price to Book (P/B)15.22
Price to Sales (P/S)2.58
P/FCF Ratio24.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthNear-10% annual revenue growth indicates expanding demand and successful commercial execution across the core diagnostics and research business. That pace supports durable top-line momentum, enabling reinvestment in product capabilities and scaling fixed-cost leverage over the next several quarters.
High Gross And Net MarginsRobust gross margin near 63% and healthy net margin reflect structural pricing power and efficient operations in a specialized medical diagnostics niche. Sustainable margins provide buffer against cost volatility and fund R&D and sales investments that reinforce competitive positioning long-term.
Very Strong Return On EquityAn ROE approaching 79% signals highly efficient capital deployment and high profitability per unit of shareholder equity. This efficiency can drive long-term value creation if maintained, enabling accelerated earnings compounding and attractive returns on incremental investment in the business.
Bears Say
Elevated Leverage / Low Equity RatioA near-1.0 D/E and low equity ratio indicate meaningful reliance on debt to fund operations and growth. Over a multi-month horizon this raises refinancing and interest rate exposure, constrains strategic flexibility, and amplifies downside risk if revenue or margins deteriorate unexpectedly.
Declining Free Cash Flow GrowthA >30% drop in free cash flow growth is a durable red flag for internal funding capacity. Reduced FCF growth limits the company’s ability to de-lever, invest in R&D or commercial expansion, and increases dependence on external financing, undermining long-term resilience if the trend persists.
Operating Cash Flow Below Net IncomeEarnings not fully converting into operating cash suggests earnings quality or working-capital strain. Persistently weak cash conversion can force reliance on debt or equity raises to fund growth and capex, increasing dilution or leverage and weakening financial stability over subsequent quarters.
Cryosite Limited News
CTE FAQ
What was Cryosite Limited’s price range in the past 12 months?
Cryosite Limited lowest share price was AU$0.60 and its highest was AU$1.30 in the past 12 months.
What is Cryosite Limited’s market cap?
Cryosite Limited’s market cap is AU$56.13M.
When is Cryosite Limited’s upcoming earnings report date?
Cryosite Limited’s upcoming earnings report date is Aug 21, 2026 which is in 108 days.
How were Cryosite Limited’s earnings last quarter?
Cryosite Limited released its earnings results on Feb 26, 2026. The company reported AU$0.023 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.023.
Is Cryosite Limited overvalued?
According to Wall Street analysts Cryosite Limited’s price is currently Overvalued.
Does Cryosite Limited pay dividends?
Cryosite Limited pays a Annually dividend of AU$0.02 which represents an annual dividend yield of N/A. See more information on Cryosite Limited dividends here
What is Cryosite Limited’s EPS estimate?
Cryosite Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cryosite Limited have?
Cryosite Limited has 48,809,563 shares outstanding.
What happened to Cryosite Limited’s price movement after its last earnings report?
Cryosite Limited reported an EPS of AU$0.023 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cryosite Limited?
Currently, no hedge funds are holding shares in AU:CTE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cryosite Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.34%
12-Months-Change
Fundamentals
Return on Equity
72.82%
Trailing 12-Months
Asset Growth
39.09%
Trailing 12-Months
Company Description
Cryosite Limited
Cryosite Limited offers outsourced clinical trials logistic services in Australia. It operates through two segments, Clinical Trials and Biological Services Logistics, and Cord Blood and Tissues Storage. The Clinical Trials and Biological Services Logistics segment provides specialist temperature-controlled storage, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns management, comparator sourcing, import, export, validated transport, and biological storage solutions to the clinical trials, and research and pharmaceutical industry. The Cord Blood and Tissues Storage segment offers long term storage solutions for cord blood and tissue samples. It serves research, medical, pharmaceutical, veterinary, and biotechnology industries. The company was incorporated in 1999 and is based in South Granville, Australia.
Technical Analysis
BCAL Diagnostics Limited
―
Rhythm Biosciences Ltd.
―
Lumos Diagnostics Holdings Ltd.
―
Inoviq Ltd
―
Microba Life Sciences Limited
―
Options Prices
Currently, No data available
---